SVB Securities analyst Mani Foroohar lowered the firm’s price target on Ionis Pharmaceuticals to $27 from $34 after the company reported 2022 financial results and provided an update on upcoming pipeline catalysts and guidance as the company enters a period of substantial capital investment and infrastructure buildout. The firm keeps a Market Perform rating on the shares.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on IONS:
- Ionis Pharmaceuticals price target lowered to $40 from $44 at Barclays
- Ionis Pharmaceuticals sees FY23 revenue $575M, consensus $672.18M
- Ionis Pharmaceuticals reports Q4 EPS (37c), consensus (92c)
- Ionis reports fourth quarter and full year 2022 financial results
- Ionis Pharmaceuticals: GSK advances bepirovirsen into Phase 3 development
